Despite its initial role in managing locally advanced breast cancer, NACT is now widely provided for patients with triple-negative breast cancer (TNBC), human epidermal growth factor receptor-2-positive (HER-2 positive) breast cancer, and early stage breast cancer [3–6]. Here, ERBB2 is linked to breast carcinoma.